Visceral leishmaniasis mimicking as second line anti retroviral therapy failure

Internal Medicine

Volumn 50, Issue 22, 2011, Pages 2855-2858

  Yanamandra, Uday ^a   Jairam, Anantaram ^a   Shankar, Subramanian ^a   Negi, Rakhi ^a   Guleria, Bupesh ^a   Nair, Velu ^a  

^a ARMED FORCES MEDICAL COLLEGE   (India)

Author keywords

AIDS; Amphotericin B; HIV; Second line ART failure; Visceral leishmaniasis

Indexed keywords

AMIKACIN; ANTIRETROVIRUS AGENT; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; MEROPENEM; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TUBERCULOSTATIC AGENT; VANCOMYCIN; ZIDOVUDINE;

ADULT; AMASTIGOTE; ARTICLE; BONE MARROW; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOADING DRUG DOSE; MALE; MIXED INFECTION; PATIENT COMPLIANCE; SEROLOGY; TREATMENT FAILURE; VISCERAL LEISHMANIASIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; INDIA; LEISHMANIASIS, VISCERAL; MALE; TREATMENT FAILURE;

EID: 81155153666     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5617     Document Type: Article

References (14)

1. Report of fifth consultative meeting on leishmania/HIV Coinfection, Adddis Ababa, Ethiopia, 20-22 March 2007; WHO/CDS/NTD/IDM/2007.5.
2. Singh S. New developments in diagnosis of leishmaniasis. Indian J Med Res 123: 311-330, 2006.
3. Sundar S, Reed S, Singh V, Kumar P, Murray H. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 351: 563-565, 1998.
4. Sinha PK, Pandey K, Bhattacharya SK. Diagnosis & management of leishmania/HIV co-infection. Indian J Med Res 121: 407-414, 2005.
5. Nigro L, Cacopardo B, Preiser W, et al. In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from HIV/Leishmania co-infected subjects. Am J Trop Med Hyg 60: 142-145, 1999.
6. Preiser W, Cacopardo B, Nigro L, et al. Immunological findings in HIV-Leishmania co-infection. Intervirology 39: 285-288, 1996.
7. del Mar Sanz M, Rubio R, Casillas A, et al. Visceral leishmaniasis in HIV infected patients. AIDS 5: 1272-1274, 1991.
8. Alavr J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334-359, 2008.
9. Murray HW. Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDs 13: 459-465, 1999.
10. Rosenthal E, Marty P, Poizot MI, et al. Visceral leishmaniasis and HIV-1 co-infection in Southern France. Trans R Soc Trop Med Hyg 89: 159-162, 1995.
11. Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 58 (No. RR-4): 101-102, 2009.
12. Meyerhoff A. US FDA approval of AmBisome (liposomal Amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 28: 42-48, 1999.
13. Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 15: 593-598, 2002.
14. Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin Pharmacother 6: 2821-2829, 2005.